Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024 Mar 20. doi: 10.1007/s40121-024-00939-w
Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A, Sundaram V, Perdrizet J. Assessing public health impact of five pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023 Jul;12(7):1809-21. doi: 10.1007/s40121-023-00828-8
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States. Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x
Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12(3):933-50. doi: 10.1007/s40121-023-00767-4
Gerbasi ME, Goss D, Petrillo J, Nejati M, Lewis S. Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research. Poster presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders; August 27, 2023. Copenhagen, Denmark. [abstract] Mov Disord. 2023; 38(Suppl 1).
Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Evaluating patients' preferences for parkinson's disease treatments. Poster presented at the MDS Virtual Congress 2021; September 17, 2021. [abstract] Mov Disord. 2021 Sep; 36(S1).
Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman DM. Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium. Infect Dis Ther. 2021 Jul 12. doi: 10.1007/s40121-021-00485-9
Serbin M, Odak S, Macahilig C, Joshi N, Shah A, Ng X, Olson K, Liang G, Klepitskaya O, Yonan C. Motor fluctuations in a real‐world sample of patients with parkinson's disease. Poster presented at the MDS Virtual Congress 2020; September 2020. [abstract] Mov Disord. 2020 Sep 11; 35(Suppl 1):S142. doi: 10.1002/mds.28268
Serbin M, Odak S, Macahilig C, Joshi N, Shah A, Ng X, Olson K, Liang G, Klepitskaya O, Yonan C. Real-world healthcare resource utilization in patients with parkinson's disease and motor fluctuations. Poster presented at the 2020 MDS Virtual Congress; September 2020. [abstract] Mov Disord. 2020 Sep; 35(Suppl 1):S142.
Thach A, Sutphin J, Coulter J, Mansfield C. A discrete-choice experiment evaluating preferences for on-demand treatments for patients with Parkinson's Disease and “OFF” episodes. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427. doi: 10.1002/mds.28268
Thach A, Coulter J, Leach C, Sutphin J, Mansfield C. On-demand treatment preferences of patients with Parkinson's Disease and “OFF” episodes: heterogeneity across patient subgroups. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427-8. doi: 10.1002/mds.28268
Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6
Sacco P, Myers K, Poulos C, Sweeney C, Hollis K, Snow V, Vietri JT. Preferences for adult pneumococcal vaccine recommendations among United States health care providers. Infect Dis Ther. 2019 Dec;8(4):657-70. doi: 10.1007/s40121-019-00266-5
Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4
Wasserman MD, Sings HL, Wilson MR, Postma MJ, Breton MC, McDade C, Farkouh RA. Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada: leveraging real-world experience from Belgium. Infect Dis Ther. 2019 Mar;8(1):1-3. doi: 10.1007/s40121-018-0222-1
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1
Parikh RC, McLaurin KK, Margulis AV, Mauskopf J, Ambrose CS, Pavilack M, Candrilli SD. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017 Dec;6(4):477-86. doi: 10.1007/s40121-017-0167-9
Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.
Edin HM, DiBenedetti D, Hill CD. Adherence among patients with Parkinson's Disease taking ropinirole immediate release at least three times daily. Poster presented at the Movement Disorders Society; June 13, 2008. [abstract] Mov Disord. 2008; 23:S344-5.
Hagell P, Whalley D, McKenna SP, Lindvall 0. Health status measurement in Parkinson's disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord. 2003 Jul 1;18(7):773-83.